Glooko acquires fellow diabetes management company DIABNEXT and more digital health briefs

Digital diabetic issues administration business Glooko has acquired Paris-based DIABNEXT, a fellow diabetes treatment platform.

DIABNEXT’s application tracks individual diabetes metrics, enabling vendors to monitor that information and deliver care remotely. Glooko reported it will offer you its own system and DIABNEXT, rebranded as Glooko XT, for the French industry.

“We are quite delighted to welcome the DIABNEXT staff to Glooko and especially energized to insert their perfectly-regarded product to Glooko’s portfolio, together with their abilities in the diabetes community in France,” Glooko CEO Russ Johannesson stated in a assertion. 

“The addition of DIABNEXT expands our choices with a one of a kind platform that can support us superior customize the affected individual practical experience and improve wellness results for folks with diabetes. Glooko’s acquisition of DIABNEXT further more cements our dedication to maximize our world wide existence and continue to generate impressive solutions.”

This is Glooko’s 2nd acquisition this yr. In January, the company declared it had obtained Berlin-primarily based xbird, maker of AI-primarily based diabetic issues treatment resources. The organization elevated $30 million in Sequence D funding final yr. 

Papa, which offers in-home support for seniors or other susceptible populations, declared Wednesday it is growing into the employer market.

The startup reported partnerships with employers will supply caregiving support for personnel who have to aid elderly, chronically sick or disabled loved ones users in addition to their paid out get the job done. 

“For employees, the not possible balancing act amongst one’s perform and family roles impacts them, their dependents, and ultimately their employer,” Andrew Parker, founder and CEO of Papa, explained in a assertion.

“Papa has shown achievements with Medicare Edge and Medicaid associates in phrases of diminished loneliness and enhanced health, and we consider there is tremendous chance to extend our product to adaptable household care, for aid when, the place, and how it is really most wanted.”

In late 2021, Papa scooped up $150 million in Sequence D funding.

Electronic serious-problem administration company Lark Wellbeing is developing an AI-enabled platform for stopping and managing atherosclerotic cardiovascular sickness (ASCVD) and coronary artery condition (CAD) in partnership with Roche Diagnostics.

The Lark Coronary heart Wellness plan, which is established to launch later on this yr, employs the concepts of cognitive behavioral treatment to present coaching close to healthy behaviors and reducing anxiety. 

“Lark Heart Health and fitness will help those at large threat prevent and actively deal with cardiovascular sickness by way of personalized electronic coaching,” cofounder and CEO Julia Hu stated in a statement. “By leveraging our AI know-how, we can provide significant and partaking treatment at an unparalleled scale, and this collaboration with Roche Diagnostics will help the expansion of our tested tech system into a single of the costliest chronic disorder marketplaces.”